Last week, BioGiv had the privilege of attending and presenting at the MIXiii Health-Tech.IL 2025 conference in Jerusalem. It was an incredible opportunity to showcase our mission and connect with so many innovative leaders in the health-tech and life sciences sectors.
The conference was packed with insightful panels, groundbreaking discussions, and fantastic networking opportunities. We were excited to engage with like-minded professionals, share ideas, and explore the future of healthcare technology.
Pepticom Ltd., one of BioGiv’s innovative resident companies, is excited about the ongoing transformation in the pharmaceutical industry, driven by Artificial Intelligence (AI). In a recent post, Pepticom's CEO shared insights from the J.P. Morgan Healthcare Investment Conference, highlighting the growing impact of AI on drug discovery and the future of healthcare.
We’re thrilled to announce that DairyX, one of BioGiv’s resident companies, has successfully completed a proof of concept for upcycling genetically modified yeast in sustainable protein production. In collaboration with Yeap, DairyX has turned yeast byproducts, which would otherwise contribute over 50% of their carbon footprint, into valuable resources.
We are delighted to share that Nectin Therapeutics has entered into a significant global license agreement with Immunome, Inc. Through this agreement, Immunome gains exclusive rights to a novel panel of antibodies targeting an undisclosed new target.
The Hebrew University websites utilize cookies to enhance user experience and analyze site usage. By continuing to browse these sites, you consent to our use of cookies.
